Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Macitentan
Drug ID BADD_D01336
Description Macitentan is a dual endothelin receptor antagonist used in the treatment of pulmonary arterial hypertension.[L35890] It was first approved by the FDA in 2013. Macitentan differs from its predecessor [bosentan] due to its lower risk of hepatotoxicity.
Indications and Usage Macitentan is indicated for the treatment of WHO group 1 pulmonary arterial hypertension (PAH) both alone and in combination with tadalafil.[L39105, L39105]
Marketing Status approved
ATC Code C02KX04
DrugBank ID DB08932
KEGG ID D10135
MeSH ID C533860
PubChem ID 16004692
TTD Drug ID D0S7JH
NDC Product Code 65015-872; 11722-058; 66215-501; 68225-070; 69037-0030; 76397-014; 59651-122; 82245-0117; 69766-006
UNII Z9K9Y9WMVL
Synonyms macitentan | N-(5-(4-bromophenyl)-6-(2-(5-bromopyrimidin-2-yloxy)ethoxy)pyrimidin-4-yl)-N'-propylaminosulfonamide | ACT 064992 | ACT064992 | ACT-064992 | Actelion-1 | opsumit
Chemical Information
Molecular Formula C19H20Br2N6O4S
CAS Registry Number 441798-33-0
SMILES CCCNS(=O)(=O)NC1=C(C(=NC=N1)OCCOC2=NC=C(C=N2)Br)C3=CC=C(C=C3)Br
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Chromaturia20.02.01.0020.002491%
Chronic obstructive pulmonary disease22.03.01.0070.008195%Not Available
Coccydynia15.02.01.0040.000265%Not Available
Colon cancer16.13.01.001; 07.21.01.0010.000722%Not Available
Condition aggravated08.01.03.0040.022769%Not Available
Cor pulmonale24.08.03.001; 22.06.01.003; 02.05.03.0010.000602%Not Available
Coronary artery disease24.04.04.006; 02.02.01.0010.000746%Not Available
Coronary artery occlusion24.04.04.013; 02.02.01.006; 12.02.01.0360.000181%Not Available
Cough22.02.03.0010.038401%
Crepitations08.01.03.0060.000120%Not Available
Cyanosis23.06.04.005; 02.11.04.004; 24.03.01.007; 22.02.02.0070.001781%
Cyst08.03.05.001; 16.02.02.0020.000915%Not Available
Deafness04.02.01.0010.001552%Not Available
Death08.04.01.0010.133603%
Decreased activity19.11.01.002; 08.01.01.0060.000530%Not Available
Decubitus ulcer23.03.11.0060.000626%Not Available
Dehydration14.05.05.0010.005981%
Dementia19.20.02.001; 17.03.01.0010.001661%Not Available
Diabetes mellitus14.06.01.001; 05.06.01.0010.002335%Not Available
Diabetic neuropathy17.09.04.002; 14.07.04.003; 05.07.04.0030.000301%Not Available
Diaphragmatic paralysis17.01.04.014; 22.09.02.0020.000265%Not Available
Diarrhoea haemorrhagic24.07.02.004; 07.02.01.0020.000181%Not Available
Dizziness17.02.05.003; 02.11.04.006; 24.06.02.0070.029881%
Dizziness exertional02.11.04.007; 24.06.02.018; 17.02.05.0340.000120%Not Available
Dizziness postural02.11.04.008; 24.06.02.008; 17.02.05.0040.000445%Not Available
Dry throat22.12.03.005; 07.06.01.0050.000614%Not Available
Duodenal ulcer haemorrhage24.07.02.020; 07.04.02.0040.000120%Not Available
Dyslexia19.21.01.003; 17.02.03.0090.000265%Not Available
Dyspepsia07.01.02.0010.006968%
Dysphonia22.12.03.006; 19.19.03.002; 17.02.08.0040.003562%
The 3th Page    First    Pre   3 4 5 6 7    Next   Last    Total 16 Pages